Please use this identifier to cite or link to this item:
Title: Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
Author: Marcé, Sílvia
Xicoy, Blanca
García, Olga
Cabezón, Marta
Estrada, Natalia
Vélez, Patricia
Boqué, Concepción
Sagüés, Miguel
Angona, Anna
Teruel Montoya, Raúl
Ferrer Marín, Francisca
Amat, Paula
Hernández Boluda, Juan Carlos
Ibarra, Mariana
Anguita, Eduardo
Cortés, Montserrat
Fernández Ruiz, Andrés
Fontanals, Sandra
Zamora, Lurdes
Grupo Español de Leucemia Mieloide Crónica (GELMC)
Keywords: Leucèmia mieloide
Expressió gènica
Myeloid leukemia
Gene expression
Issue Date: 16-Jul-2021
Publisher: MDPI
Abstract: The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.
Note: Reproducció del document publicat a:
It is part of: Journal of Clinical Medicine, 2021, vol. 10, num. 14, p. 3146
Related resource:
ISSN: 2077-0383
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
jcm-10-03146-v2.pdf1.16 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons